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Venous thrombi are intravascular deposits composed
predominantly of fibrin and red blood cells with a vari-
able platelet and leukocyte component. They frequently
arise in large venous sinuses in the calf, in valve cusp
pockets either in the deep veins of the calf or thigh or
in venous segments that have been exposed to direct
trauma. Venous thrombosis can be produced experi-
mentally by a combination of stasis and systemic hy-
percoagulability or by stasis and endothelial damage.
Thrombosis is augmented if the fibrinolytic mechanism
is inhibited or defective. A number of clinical conditions
and laboratory abnormalities are associated with and
predipose to venous thrombosis and, in many of these,
it is possible to identify one or more of the thrombogenic
factors discussed.
Venous thromboembolism (venous thrombosis and
pulmonary embolism) is a serious and potentially fatal
disorder that usually complicates the course of sick hos-
pitalized patients, but occasionally affects ambulant and
Epidemiology
Venous thrombosis can involve the superficial leg veins,
deep veins of the calf (calf vein thrombosis) and deep veins
above the knee (popliteal and more proximal veins [proximal
vein thrombosis]). Thrombosis of the superficial veins of the
legs frequently occurs in varicosities and is usually benign
and self-limiting. Thrombosis of the deep calf vein is a less
serious disorder than proximal vein thrombosis because the
thrombi are generally smaller in patients with calf vein
thrombosis and are less frequently associated with clinical
disability or major complications.
Incidence. Deep venous thrombosis and pulmonary em-
bolism usually complicate the course of sick hospitalized
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otherwise healthy individuals. Screening studies with
iodine-l25 fibrinogen leg scanning, impedance plethys-
mography and perfusion lung scanning have shown that
the majority of venous thrombi and pulmonary emboli
that occur in hospitalized patients are small and asymp-
tomatic, and it is likely that most are clinically insignif-
icant. In bedridden patients, most thrombi commence
in the calf and are asymptomatic. When a calf vein
thrombus extends into the proximal venous segment, the
risk of clinically significant pulmonary embolism in-
creases. Less is known about the incidence and clinical
significance in a nonhospital population; although
asymptomatic disease occurs, its frequency is unknown.
In contrast to the patients with asymptomatic venous
thrombosis, symptomatic patients with venous throm-
bosis usually have large occulsive thrombi localized in
their proximal veins.
(J Am Coli CardioI1986;8:104B-113B)
patients, but it is clear from recent studies (1-4) that venous
thromboembolism also affects ambulant and otherwise healthy
individuals. Over the last decade, screening studies (5) with
iodine-l 25 fibrinogen leg scanning have shown that venous
thrombosis is common in hospitalized patients, but that more
than 80% of the thrombi detected are small, asymptomatic,
confined to the calf and probably clinically insignificant.
Autopsy studies (6) have also demonstrated a high frequency
of pulmonary embolism, which although the majority are
small and clinically insignificant, the fact remains that fatal
pulmonary embolism is one of the most common prevent-
able causes of hospital death. Fatal pulmonary embolism
has been reported (7,8) in 4 to 7% of patients after emer-
gency hip surgery, in 0.3 to 1.7% of patients after elective
hip replacement and 0.1 to 0.8% of general surgical patients.
The frequency and distribution of venous thromboem-
bolism in ambulatory patients has been much more difficult
to study. However, as mentioned, recent experience since
the provision of a noninvasive diagnostic service indicates
that venous thrombosis is not uncommon in ambulant non-
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hospitalized patients. When patients with venous thrombosis
develop symptoms, they usually have large occlusive thrombi,
'and approximately 80% of these are either located or extend
into the popliteal or more proximal veins at the time of
presentation (3,9). Symptomatic pulmonary embolism oc-
curs in ambulant patients (3) more frequently than is gen-
erally appreciated, but fatal pulmonary embolism is uncom-
mon.
Fate of venous thrombosis. When symptoms or signs
of venous thrombosis occur, they are caused either by ob-
struction to venous outflow, inflammation of vessel wall or
perivascular tissue, a combination of these two factors or
embolization of the thrombus into the pulmonary circula-
tion. The fate of a venous thrombus is determined by the
balance between factors that either promote further depo-
sition of fibrin onto the thrombus or that lead to its removal.
Extension of thrombosis is more likely to occur if the orig-
inal thrombogenic stimulus persists (for example, tissue in-
jury, stasis or vascular damage) or if marked endothelial
damage or stasis occurs as a consequence of the original
acute venous thrombosis. The factors that lead to the re-
moval of thrombi are fibrinolysis, digestion of fibrin by
leukocytes, organization of the thrombus and embolization.
Complete spontaneous lysis of large venous thrombi is un-
common and, even when patients with venous thrombosis
are treated with heparin, complete lysis occurs in less than
10% of cases (10,11). In contrast, complete dissolution of
small, asymptomatic calf vein thrombi (detected by iodine-
125 fibrinogen leg scanning) occurs quite frequently (5).
Pulmonary embolism is commonly associated with ve-
nous thrombosis. Clinically silent pulmonary embolism (de-
tected by perfusion lung scanning) occurs at the time of
presentation in about 50% of patients with documented vein
thrombosis (12,13). Pulmonary emboli occur more fre-
quently and are larger in patients with proximal vein throm-
bosis than in patients with calf vein thrombosis (3).
Asymptomatic venous thrombosis is also found in ap-
proximately 70% of patients who present with confirmed
clinically symptomatic pulmonary embolism (3) and is usu-
ally extensive, involving the proximal veins. If the thrombus
that embolizes is small (which is frequently the case when
it is present in the calf), the embolus is usually asymptomatic
and clinically insignificant (12). However, if it is large and
involves the proximal veins, it may produce clinical man-
ifestations (3) and, if it is very large or if the patient has a
compromised cardiorespiratory system, it may be fatal. Most
clinically significant and fatal emboli arise from thrombi in
the proximal veins of the leg (2).
Venous thrombi usually slowly organize and recanalize
and may predispose patients to the postphlebitic syndrome
because of associated venous valve damage (14). In addi-
tion, patients with one episode of venous thrombosis are
predisposed to further episodes when exposed to high risk
situations (15,16).
Pathogenesis of Venous Thromboembolism
Venous thrombi are composed predominantly of fibrin
and red blood cells with a variable platelet and leukocyte
component (17). They frequently arise in large venous si-
nuses in the calf, in valve cusp pockets either in the deep
veins of the calf or thigh (18,19) or in venous segments that
have been exposed to direct trauma (20,21).
Experimental venous thrombosis can be produced by a
combination of stasis and an increase in blood coagulability
or by a combination of stasis and endothelial damage (22,23).
Predisposing factors. Clinically, the major predispos-
ing factors to venous thrombosis are activation of blood
coagulation, venous stasis and vascular wall damage
(21,22,24). These three factors are interrelated and, thus,
venous thrombosis may occur when blood coagulation is
activated by the release of tissue thromboplastin from in-
jured or infarcted tissue (25-27) or when blood coagulation
is activated locally by vessel wall damage (20,24). The
thrombogenic effect of activation of blood coagulation is
augmented by venous stasis and reduced by rapid blood
flow. For example, as discussed later, one of the reasons
is that venous stasis impairs the clearance of activated co-
agulation factors by the liver and results in an increase in
the concentration of activated coagulation factors through
the autocatalytic activity of the coagulation system (22,28).
Thrombogenesis. Thrombogenesis is modulated by in-
activation of activated coagulation factors by circulating
inhibitors (29-32), the dissolution and clearance of activated
coagulation factors by flowing blood, the removal of acti-
vated coagulation factors by the liver (33), the clearance of
soluble fibrin complexes by reticuloendothelial cells (34)
and the dissolution of fibrin by the fibinolytic system (35).
Thrombogenic Factors
Activation of Blood Coagulation
The coagulation proteins circulate as proenzymes that are
sequentially converted to active enzymes, all of which are
serine proteases (28). The blood coagulation process can be
activated by the intrinsic or extrinsic pathway (36), and this
has been reviewed in the first section of this symposium.
In brief, intrinsic pathway activation occurs when blood
comes in contact with a foreign surface (37). Factor XII
interacts with the surface and is converted into its active
form-factor XIIa. This, in tum, converts the zymogen
factor XI into factor XIa, a reaction that is calcium-
independent; all subsequent reactions except the conversion
of fibrinogen to fibrin require calcium. Factor XIa, in tum,
activates factors IX and IXa in the presence of factor VIII,
and phospholipid activates factor X. The rate of this reaction
is greatly increased by the presence of phospholipid and by
prior exposure of factor VIII to either thrombin or factor
Xa (38,39).
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The extrinsic pathway is activated in vitro by exposing
blood to phospholipoprotein extracts from various tissues
(such as brain or lung), which are known as thromboplastins.
Tissue thromboplastin combines with and activates factor
VII and the resulting factor VII complex, in tum, activates
factor X, thus bypassing a number of time-consuming steps
in the intrinsic clotting pathway (40,41).
The intrinsic and extrinsic pathways meet at a common
point at the activation of factor X; beyond this point, blood
coagulation continues along a common pathway. Activated
factor X in the presence of calcium, phospholipid and factor
V converts prothrombin to thrombin. This reaction is also
markedly accelerated by prior exposure of factor V to throm-
bin. Thrombin interacts with fibrinogen and converts it into
fibrin monomer and fibrinopeptides A and B. The fibrin
monomer fragments polymerize to form fibrin polymers,
which precipitate as insoluble fibrin when a critical con-
centration of fibrin monomer is reached (42). The fibrin
polymers are initially linked by noncovalent bonds, but be-
come covalently bound under the influence of activated fac-
tor XIII (43).
Interactions between intrinsic and extrinsic path-
ways. Blood coagulation is modified by a number of pos-
itive and negative feedback loops and by interaction between
the intrinsic and extrinsic pathways. For example, thrombin
and factor Xa, formed either by activation of the extrinsic
or intrinsic pathway, feed back to activate factors VIII and
V and markedly accelerate the rate of reactions involving
these two cofactors (36,39,44). Factor Xa feeds back to
initially increase and then inhibit its activation by factor VII
(41,45). The intrinsic and extrinsic pathways are linked in
a number of ways. Factor VII is activated by factor XIIa
(46), and factor VIla can activate factor IX directly (44,45,47).
There is also evidence that the activation of factor XI can
occur independently of factor XII through a platelet-related
reaction (48).
Mechanisms for activation of venous blood coagula-
tion. The precise mechanism or mechanisms for activation
of blood coagulation, particularly for the venous system, is
uncertain. There are a number of theoretic possibilities.
Activation of the intrinsic pathway may occur by contact
of factor XII with collagen on the exposed subendothelium
of damaged vessels (49,50). Coagulation may be further
augmented through a platelet-related mechanism because
platelets that have been exposed to collagen or adenosine
diphosphate (ADP) accelerate the activation of factors XII
and XI (48). The extrinsic pathway may be activated by the
release of tissue thromboplastin into the bloodstream during
cell damage (25,27) and by the exposure of blood to tissue
thromboplastin, which is made available locally as a result
of vascular wall damage (51) and by activated leukocytes
that migrate to areas of vascular damage (52,53). Factor X
can be activated directly by extracts of malignant cells that
contain a cysteine protease (54), and this may be one of the
mechanisms by which thrombosis is induced in patients with
malignant disease.
A number of clinical risk factors could induce venous
thromboembolism by activating blood coagulation (21). These
include extensive surgery (55), trauma (56), bums (56),
infusion of factors II, VII and IX and X complex (for the
treatment of bleeding associated with factor IX deficiency
or liver disease) which contain activated clotting factors,
(57) disseminated malignant disease (54,57) and myocardial
infarction (26).
Venous Stasis
Stasis predisposes to venous thrombosis by preventing
activated coagulation factors from being diluted by non-
activated blood, preventing clearance of activated coagu-
lation factors, and preventing mixing of activated coagu-
lation factors with their inhibitors (21,22).
Physiologically, venous return from the legs is enhanced
by contraction of calf muscles, which propels blood from
the calf in the direction of the heart (59-61). Venous stasis
is produced by immobility, venous obstruction, raised ve-
nous pressure, increased blood viscosity and venous dila-
tion.
Immobility. This predisposes to venous stasis and,
therefore, thrombosis because it promotes blood pooling in
the intramuscular sinuses of the calf (18,59,61), which are
dilated with blood during recumbency (15,19). Thus, the
prevalence of venous thrombosis found at autopsy increases
steeply in patients who are confined to bed for more than
1 week before death (59). Preoperative immobility is also
associated with a higher frequency of preoperative venous
thrombosis (62,63). Postoperative patients remain at risk
during the entire period of immobility, and late postoper-
ative thrombosis is not prevented in patients who have pro-
phylaxis in the first postoperative week (either with low
dose heparin or with intermittent pneumatic compression)
if they remain immobile beyond the period of prophylaxis
(64,65). Immobility contributes to the higher incidence of
postoperative venous thrombosis in patients who undergo
hysterectomy or prostectomy using the abdominal route than
in those who have vaginal hysterectomy and transurethral
prostatectomy (15,66-70). Immobility also contributes to
the high frequency of thrombosis after hip surgery (20,
70-73) and knee surgery (74,75) and in patients who have
fractures of the lower limb.
The effect of immobility on thrombosis is well illustrated
by comparing the location of thrombosis in stroke patients
(76,77) with that in paraplegic patients (78). Venous throm-
bosis is a common complication in both groups, but the
frequency of thrombosis is four to nine times greater in the
paralyzed than in the nonaffected limb in patients with stroke;
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it occurs with equal frequency in both legs in paraplegic
patients (76,78). Immobility also contributes to the high
prevalence of thrombus in patients with cardiac failure and
other serious medical illnesses.
Venous obstruction. This may occur as a result of either
extrinsic compression or intraluminal obstruction secondary
to a previous venous thrombosis. Stasis produced by venous
obstruction probably contributes to the risk of venous throm-
bosis in patients with pelvic tumor and to recurrent venous
thrombosis in patients with persistent obstruction due to
proximal vein thrombosis (79).
Elevated venous pressure. This produces venous stasis
and predisposes to the high prevalence of venous thrombosis
in patients with heart failure (80,81).
Blood viscosity. Blood flow and blood viscosity are
closely linked (82). Blood viscosity increases in regions of
slow flow. However, blood viscosity is increased in poly-
cythemia vera and erythrocytosis (because of hypergam-
maglobulinemia) and in some postoperative patients and
inflammatory states (because of an increase in fibrinogen
concentration) (83,84). It is possible that the increased prev-
alence of venous thrombosis in these conditions is caused
by stasis induced by an increase in blood viscosity.
Venous dilation. This occurs in patients with varicose
veins and in elderly patients (particularly if they are bed-
ridden), during pregnancy (85) and in individuals taking
estrogen-containing oral contraceptive pills (85). Stasis due
to venous dilation could contribute to the increased risk of
thrombosis in these patient groups.
Vessel Wall Damage
As discussed, damage to the venous endothelium results
in the exposure of blood to subendothelium, which in tum
leads to platelet adhesion and aggregation (23,86), local
accumulation of leukocytes (53), activation of the intrinsic
pathway through activation of factor XII by collagen (49)
and activation of factors XII and XI by activated platelets
(48). Activation of the extrinsic pathway also occurs by
tissue thromboplastin derived from the damaged vessel wall
(51) and activated leukocytes (87).
Venous damage is probably the main contributor to ve-
nous thrombosis in patients undergoing hip surgery (20),
knee surgery and varicose vein stripping in patients with
severe bums and lower limb trauma (56).
Protective Mechanisms
These mechanisms will be described in more detail than
in previous sections since their preventive role in venous
thromboembolic disease is better known. On the other hand,
a decrease or absence of one of these protective mechanisms
may predispose to venous thrombosis.
Circulating Inhibitors
Three plasma proteins have been identified as important
modulators of activation of blood coagulation. These are
antithrombin III, protein C and protein S.
Antithrombin III. This is an important coagulation in-
hibitor (30,31,88). It inhibits activated factors XII, XI, IX,
X and thrombin (although inhibition of factors XIIa and XIa
is relatively minor), and the rate of its inhibition of these
enzymes is markedly increased by heparin (30,31).
Reduction of antithrombin III levels to approximately
50% of normal predisposes to venous thrombosis (89-94).
Although antithrombin III is a relatively slow inactivator of
these activated clotting factors in the absence of heparin, a
heparin-like glycosaminoglycan has been reported (95,96)
on the luminal surface of endothelial cells, so that a 50%
reduction in antithrombin III might seriously limit the neu-
tralization of activated coagulation factors on endothelial
surface.
Thrombin binds to receptors on the endothelial cell sur-
face, where it is inactivated by circulating antithrombin III.
One of these receptors is thrombomodulin, and others may
be glycosaminoglycan bound to endothelium. Thrombin bound
to endothelium is rapidly inactivated in the presence of
plasma, but only slowly if the plasma is replaced by either
antithrombin III or antithrombin III-depleted plasma. Thus,
potentiation of the inhibition of endothelial cell-bound
thrombin by glycosaminoglycan appears to be dependent on
the presence not only of antithrombin III, but also of an
additional plasma factor.
There have been a number of reports (89-94) of idio-
pathic and secondary venous thrombosis occurring in fam-
ilies with a deficiency of antithrombin III. The trait is in-
herited in an autosomal dominant manner, and affected patients
have antithrombin III levels of 40 to 60% of normal. Al-
though it is difficult to obtain exact figures on the risk of
thrombosis in affected individuals because of the likelihood
of a reporting bias, review of the literature indicates that
more than 50% of affected individuals develop thromboem-
bolic events before the age of 50 years. Thrombosis usually
occurs in the deep veins of the legs or as a pulmonary
embolism, but there are reports (84) of thrombosis occurring
in usual sites such as the mesenteric veins.
Decreased antithrombin III levels also occur in liver
disease and during heparin therapy. In patients with liver
disease, this decrease may contribute to the increased risk
of thrombosis that has been reported (97) in these patients
after infusions of concentrates containing factors II, VII,
IX and X. There is no evidence that the mild reduction in
antithrombin III that occurs during heparin therapy is clin-
ically important.
Protein C. This is a zymogen whose synthesis is vitamin
K-dependent (98). Like other vitamin K-dependent coag-
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ulation factors. protein C contains a number of gamma-
carboxyglutamic acid residues (99). The amino acid se-
quence of bovine protein C has recently been determined
(100).
Protein C is activated by thrombin (29). The activation
process is greatly enhanced by interaction of thrombin with
the endothelial cell surface factor thrombomodulin (10 I).
Activated protein C is a potent anticoagulant (102) that
inactivates activated factors V and VIII and also stimulates
fibrinolysis (32.103). Walker (104) reported that another
vitamin K-dependent protein (protein S) is a cofactor for
activated protein C. (104).
Deficiency ofprotein C is associated with familial venous
thrombosis (105-107). Protein C deficiency is also inherited
in an autosomal dominant manner. The level of protein C
in affected members is 40 to 60% of normal. similar to that
seen in patients with antithrombin III deficiency. Most pa-
tients have venous thromboembolism. Mesenteric vein
thrombosis has also been described, and there have been
isolated reports of stroke and myocardial infarction occur-
ring at a relatively early age. However, there is no con-
vincing evidence that protein C predisposes to arterial
thrombosis.
Protein S. This is a vitamin K-dependent plasma protein
that is a cofactor for activated protein C and is required for
the expression of the anticoagulant effect of protein C
(108-110). Despite its relatively recent discovery, protein
S deficiency has already been reported (108.111-114) in
more than 50 patients with recurrent venous thrombosis.
Venous thromboembolism is often idiopathic, may be fa-
milial and frequently occurs before the age of 30 years. The
clinical disorder affects both sexes equally, and is expressed
in heterozygotes whose levels of functional protein S are in
the range of 15 to 50% of normal (108 .11 I) . Preliminary
reports suggest that patients can be treated effectively with
long-term oral anticoagulant therapy.
Heparin cofactor II. This is a plasma protein that in-
hibits thrombin activity by forming a covalent complex with
the enzyme. The formation of the complex is catalyzed by
heparin and dermatan sulfate. There have been two reports
of thrombosis associated with heparin cofactor deficiency,
but a definite causal relation has not been established (115).
Hepatic Inactivation of Activated
Coagulation Factors
The liver removes activated coagulation factors from blood
(33). Thrombosis has been reported in patients with liver
disease after the infusion of concentrates of factors II, VII,
IX and X (57). These concentrates contain a small amount
of activated coagulation factors, which may not be ade-
quately cleared in patients with liver disease and, thus, lead
to thrombosis (57,116,117).
Fibrinolytic System
The basic reaction of the plasma fibrinolytic system is
the conversion of beta-globulin plasminogen to plasmin by
proteolytic cleavage mediated by a number of plasminogen
activators (35,118). At least two plasminogen activators.
tissue plasminogen activator and urokinase. are synthesized
by and released from endothelial cells. Plasmin has the
capacity to hydrolyze fibrin (the desired physiologic sub-
strate) and various plasma coagulation proteins including
fibrinogen and factors VII and V (35). Like the coagulation
system, the activity of the fibrinolytic system is modulated
by inhibitors that inhibit both the activation of plasminogen
and the proteolytic effect of plasmin (35,119).
Decreased fibrinolytic activity. This has been reported
in patients in the early postoperative period (120-124), in
individuals taking oral contraceptives (125), during the last
trimester of pregnancy (126-128) and in obese individuals
(62,128,130). Fibrinolytic activity has been found to be less
in leg veins than in arm veins (131, 132), an observation
that may explain, in part. the greater tendency for venous
thrombosis to occur in leg veins. The relative deficiency of
fibrinolytic activity in leg veins appears to be more marked
in the elderly (132), which may explain, in part, the im-
portance of old age as a risk factor in thrombosis. An as-
sociation between defective fibrinolysis and postoperative
thrombosis has been observed when fibrinolytic activity is
measured preoperatively and on the first postoperative day
(120-124). Postoperative venous thrombosis has been re-
ported to occur more frequently in patients who have re-
duced fibrinolytic activity detected either as a high anti-
plasmin level or as reduced plasminogen activator level
(120-124).
Relation between reduced fibrinolytic activity and re-
current venous thromboembolism. There have been a
number of reports (132-135) that patients with recurrent
superficial and deep vein thrombosis have reduced fibri-
nolytic activity measured either as vessel wall plasminogen
activator (from biopsy specimens of superficial veins) or as
circulating plasminogen activator. In uncontrolled studies
(133,136). treatment of some of these patients with anabolic
steroids has been reported to both increase fibrinolytic ac-
tivity and reduce the frequency of recurrent venous throm-
bosis (136,137).
Recurrent venous thrombosis and pulmonary embolism
has been reported in a patient who had decreased levels of
plasminogen when measured immunologically (138). Other
members of the patient's family also had a reduced ratio of
functional to immunologic plasminogen, but did not have
a history of thrombosis. Further evidence for a relation
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between reduced fibrinolytic activity and thrombosis comes
from a report (138) of high antiplasmin levels occurring in
a family with idiopathic pulmonary hypertension.
Clinical Risk Factors and Their Relation
to Thrombogenesis
Surgery and trauma. A number of well recognized
thrombogenic factors are associated with surgery and trauma.
These include I) increased blood coagulability due to release
of tissue thromboplastin into the blood (25,27); 2) stasis
due to immobilization preoperatively, during operation and
during the postoperative period and in patients with a plaster
cast (59-63); and 3) reduced fibrinolytic activity, which
occurs in many patients within 24 hours of surgery
(119,123,124). In addition, surgery or trauma to the lower
limb may produce local vessel damage (20).
The risk of thromboembolism after surgery is related to
the site and extent of surgical trauma as well as to duration
and nature of the operative procedure and the length of time
that the patient remains immobilized preoperatively and
postoperatively (15,62,140). Orthopedic surgical proce-
dures of the lower limb and trauma to the pelvis and lower
limb carry a particularly high risk, Approximately 20% of
thrombi in patients who have hip surgery are localized to
the femoral vein close to the site of surgery (20,71,141).
Operative venography has demonstrated that the femoral
vein is markedly twisted and distorted during total hip re-
placement; it is likely that endothelial damage occurs as a
consequence of this manipulation and is responsible for the
unique localization of thrombi in the proximal venous seg-
ment (20). It is of interest that more than 90% of femoral
vein thrombi occur on the side of operation, although calf
vein thrombi tend to be evenly distributed in both legs
(20,71,141), Patients having major knee surgery or who
have sustained tibial fractures requiring cast immoblization
are also at very high risk of venous thrombosis (55).
Examples of the important role of surgical trauma and
immobilization in the risk of thrombosis are provided by
comparing the thrombosis rate for abdominal hysterectomy
with that for vaginal hysterectomy (69) and by comparing
suprapubic prostatectomy with transurethral prostatectomy
(65-67). The risk of thrombosis is much higher when these
procedures are performed by an abdominal approach.
Age. Age is a very important risk factor for venous
thrombosis, but the underlying mechanism is uncertain
(15,62). Venous dilation occurs in the elderly, particularly
when they are confined to bed, and in addition to their
greatly reduced mobility, results in venous stasis, The fi-
brinolytic response to venous occlusion of the legs is re-
ported to be significantly lower in persons older than 65
years of age than in those younger (132), These older people
have less releasable activator in endothelial cells, Other
unknown mechanisms also probably contribute to the very
high risk of venous thrombosis that occurs with advanced
age,
Malignancy. Patients with malignant disease may de-
velop recurrent superficial deep vein thrombosis, thrombosis
in unusual sites and, rarely, thrombosis that is resistant to
anticoagulant therapy, The frequency of postoperative ve-
nous thrombosis increases two- to threefold in patients
undergoing surgery for malignant disease when compared
with similar surgical procedures for nonmalignant condi-
tions (15,55,62). However, the extent of surgery could be
greater in patients with malignant disease, so that the effect
of malignancy as an independent risk factor for thrombosis
is difficult to determine in these postoperative patients (142).
A number of factors could contribute to the increased
risk ofvenous thrombosis in patients with malignant disease.
Material that has both tissue thromboplastin-like activity and
factor X-activating activity has been isolated from malignant
tissues (54,58), and patients with cancer have been reported
to have reduced fibrinolytic activity (143), Malignant tumors
may either compress or infiltrate veins and so predispose to
thrombosis. Patients with malignant disease have associated
confounding risk factors in that they tend to be older and,
as mentioned, require more extensive and prolonged surgery
than those with benign disease.
Heart failure. Heart failure is a well recognized risk
factor for venous thromboembolism, and pulmonary em-
bolism is an important cause of death in patients with heart
failure (21,81), The increased risk of venous thrombosis in
these patients is contributed to by increased central venous
pressure and mobility, both of which lead to venous stasis.
Previous venous thromboembolism. Patients with a
history of previous venous thrombosis have a three- to four-
fold increased risk of developing venous thrombosis after
elective abdominal surgery than do patients without such a
history (15,62). In addition, the rate of recurrent venous
thrombosis is three- to fourfold greater when anticoagulant
therapy is discontinued after 3 months in patients with re-
current venous thrombosis than in patients who have only
one episode of venous thrombosis (79). The increased risk
of thrombosis in patients who have had an episode of venous
thrombosis may be caused by venous stasis, which occurs
as a consequence of valve damage, or by venous obstruction
or alterations in the blood (either recognized, for example,
deficiency of antithrombin III, protein C, protein S, plas-
minogen or possibly heparin cofactor II, or unrecognized),
which predisposed the patient to the initial episode.
Obesity. A number of studies (15,62) have reported that
obesity is associated with an increased risk of postoperative
thrombosis, Obesity has been reported to be associated with
impaired fibrinolytic activity; in addition, obese patients
(129,130) are more likely to remain immobile for longer
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periods of time after operation than are their nonobese coun-
terparts.
Pregnancy and the pill. Pregnancy and the estrogen-
containing oral contraceptive pills are recognized as risk
factors for venous thrombosis. However, evidence sup-
porting pregnancy as a risk factor is imperfect, and there is
no good evidence that the "low dose" estrogen-containing
pill is a risk factor for venous thrombosis.
A number ofthrombogenicfactors operate during normal
pregnancy and delivery. These include a decrease in fibri-
nolytic activity, which occurs in the third trimester (1 26-1 28)
and in the early stages of labor before placental separation
(127), release of tissue thromboplastin into the circulation
at the time of placental separation (126), venous stasis,
which occurs as a result of deep venous dilation (85), and
pressure of the uterus during the third trimester of pregnancy
and during delivery. There is also an increased level of
plasma fibrinogen and coagulation factors VII, VIII and IX
during pregnancy, but these are unlikely to contribute to the
risk of thrombosis (126). Estrogens in oral contraceptive
pills produce many of the changes that occur in pregnancy.
They produce venous dilation (85) and, in some studies,
estrogens have been reported to decrease functional levels
of antithrombin III (144) and decrease fibrinolytic activity
(125). Estrogen also causes elevations in the level of a
number of coagulation factors, but this is unlikely to be
important in thrombogenesis (145,146).
Other clinical disorders that predispose to venous
thromboembolism. Other conditions that have been re-
ported to be associated with venous thromboembolism in-
clude thrombocytosis, polycythemia vera and systemic lu-
pus erythematosus. When thrombocytosis occurs after
splenectomy or other surgical procedures, it is transient and
not associated with an increased risk of venous thrombosis
(147,148). In contrast, thrombocytosis associated with mye-
loproliferative disorders such as polycythemia vera (149) or
with splenectomy in patients with sideroblastic anemia and
other hemolytic anemias has been reported to be associated
with an increased frequency of venous thromboembolism
(147). The mechanism of this increased tendency for throm-
bosis is uncertain, but may be due to the effect of hyperactive
platelets. Patients with polycythemia vera have the addi-
tional risk factor of high blood viscosity, which also occurs
in patients with erythrocytosis due to chronic anoxia.
Patients with systemic lupus erythematosus may have
recurrent episodes of superficial deep vein thrombosis (150).
Recently, immune complexes directed' against endothelial
cells have been described in patients with systemic lupus
erythematosus predisposed to venous thrombosis (150). The
presence of lupus-like anticoagulants in patients with sys-
temic lupus erythematosus or in otherwise normal individ-
uals has been reported to be associated with venous throm-
bosis.
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